Skip to main content

Advertisement

SpringerLink
Log in

Adherence to anti-osteoporotic therapies: role and determinants of “spot therapy”

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

A successful therapy needs high level of adherence consisting in right drug intake in terms of persistence and compliance. Our study suggests adherence is higher if spot (less than 30 days) therapies are excluded; the analysis of spot therapy causes underlines the importance of the interpersonal aspects of medical practice.

Introduction

A successful therapy needs a high level of adherence consisting in right drug intake in terms of persistence and compliance. The aim of this study was to evaluate anti-osteoporotic therapies recorded in general practitioner databases in the area of Rome, which used the same computerized medical record management. The study focused on evaluating therapy adherence, any adherence changes excluding spot therapies (less than 30 days), and any cause of early therapy discontinuation in a subgroup of patients randomly selected.

Methods

Thirty-one databases were evaluated, including a total of 6,390 anti-osteoporotic therapies: 5,853 were prescribed to women and 537 to men. The prescribed drugs were: vitamin D (13 %), calcium (8.7 %), vitamin D + calcium (40.1 %), raloxifene (3.3 %), alendronate (16.4 %), risedronate (7.7 %), clodronate (10.4 %), or other drugs (0.4 %). Spot therapies represented 53.7 % of the total prescriptions. The difference between adherence in the total group (24.64 %) and the group excluding spot therapies (43.38 %) is significant. The main factors influencing low adherence were side effects (27 %), misinformation given by the physician (17 %), insufficient motivation (9 %), difficult intake (9 %), and no perceived benefits (9 %).

Results

Our study suggests adherence is high and similar to other chronic diseases if spot therapies are excluded. The analysis of spot therapy causes suggests that an important role is played by the physician and the interpersonal aspects of medical practice, especially at the first prescriptions.

Conclusions

The physician should collaborate with patients in choosing a personalized medical treatment. Reducing spot therapy could be the real goal in order to improve anti-osteoporotic therapy adherence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Kanis JA, Cooper C, Hiligsmann M, Rabenda V, Reginster J-Y, Rizzoli R (2011) Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int 22:2565–2573

    Article  PubMed  CAS  Google Scholar 

  2. Mc Combs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48(3):271–287

    Article  CAS  Google Scholar 

  3. Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21(19):1453–1460

    Article  PubMed  CAS  Google Scholar 

  4. Penning-van Beest FJA, Erkens JA, Olson M, Herings RMC (2008) Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 19:511–517

    Article  PubMed  CAS  Google Scholar 

  5. Zambon A, Baio G, Merlino L, Mazzaglia G, Corrao G (2008) Dicontinuity and failures of therapy with bisphosphonates: joint assessment of predictors with multi-state models. Pharmacoepidem Dr S 17:260–269

    Article  CAS  Google Scholar 

  6. Gallagher A, Rietbrock S, Olson M, Van Staa TP (2008) Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 23:1569–1575

    Article  PubMed  Google Scholar 

  7. Siris ES, Harris ST, Rosen CJ, Barr CE, Abbot T (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81(8):1013–1022

    Article  PubMed  Google Scholar 

  8. Seeman E, Compston J, Adachi J, Brandi ML, Cooper C, Cramer JA (2007) Non-compliance: the Achilles’ heel of anti-fracture efficacy. Osteoporos Int 18:711–719

    Article  PubMed  CAS  Google Scholar 

  9. Sabaté E (ed) (2003) Adherence to long-term therapies: evidence for action. World Health Organization, Geneva

    Google Scholar 

  10. DiMatteo MR (2004) Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 42:200–209

    Article  PubMed  Google Scholar 

  11. Weycker D, Macarios D, Edelsberg J, Oster G (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645–1652

    Article  PubMed  CAS  Google Scholar 

  12. Rossini M, Bianchi G, Di Munno O, Giannini S, Adami S (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17(6):914–921

    Article  PubMed  CAS  Google Scholar 

  13. Rietbrock S, Olson M, vanStaa TP (2009) The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates. Q J Med 102:35–42

    Article  CAS  Google Scholar 

  14. Segal E, Shalom S (2009) Two years adherence to anti-osteoporotic medications in postmenopausal Israeli women. Arch Gerontol Geriatr 49(3):360–363

    Article  PubMed  Google Scholar 

  15. Rossini M, Viapiana O, Gatti D, James G, Girardello S, Adami S (2005) The long term correction of vitamin D deficiency: comparison between different treatments with vitamin D in clinical practice. Minerva Med Apr 96(2 Suppl 2):1–7

    CAS  Google Scholar 

  16. Segal E, Tamir A, Shalom S (2003) Compliance of osteoporotic patients with different treatment regimens. IMAJ 5:859–862

    PubMed  Google Scholar 

  17. Penning-van Beest FJA, Goettsch WG, Erkens JA, Herinhs RMC (2006) Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 28(2):236–242

    Article  PubMed  CAS  Google Scholar 

  18. Carr AJ, Thompson PW, Cooper C (2006) Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int 17:1638–1644

    Article  PubMed  CAS  Google Scholar 

  19. Hall JA, Roter DL, Katz NR (1988) Meta-analysis of correlates of provider behavior in medical encounters. Med Care 26:657–675

    Article  PubMed  CAS  Google Scholar 

  20. Stewart MA (1996) Effective physician–patient communication and health outcomes: a review. CMAJ 152:1423–1433

    Google Scholar 

  21. Roter DL, Hall JA, Aoki Y (2002) Physician gender effects in medical communication: a meta-analytic review. JAMA 288(6):756–764

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Geriatric Unit, Sant’Andrea Hospital, Sapienza University of Rome, via di Grottarossa No. 1035, 00189, Rome, Italy

    L. Tafaro & P. Falaschi

  2. FIMMG, Rome, Italy

    G. Nati, E. Leoni & M. Mei

  3. Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, Rome, Italy

    R. Baldini

  4. Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy

    M. S. Cattaruzza

Authors
  1. L. Tafaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Nati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Leoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Baldini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. S. Cattaruzza
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Mei
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. Falaschi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Falaschi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tafaro, L., Nati, G., Leoni, E. et al. Adherence to anti-osteoporotic therapies: role and determinants of “spot therapy”. Osteoporos Int 24, 2319–2323 (2013). https://doi.org/10.1007/s00198-013-2283-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-013-2283-z

Keywords

Search

Navigation